Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced bcell apoptosis

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 5001-5013

  Campion, Eva M ^a,d   Hakimjavadi, Roya ^a   Loughran, Sinéad T ^a,e   Phelan, Susan ^a   Smith, Sinéad M ^a,f   D'Souza, Brendan N ^a,g   Tierney, Rosemary J ^b   Bell, Andrew I ^b   Cahill, Paul A ^a,c   Walls, Dermot ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c DUBLIN CITY UNIVERSITY   (Ireland)

^d Atlantic Technological University   (Ireland)

^e DUNDALK INSTITUTE OF TECHNOLOGY   (Ireland)

^f TRINITY COLLEGE DUBLIN   (Ireland)

^g AMERICAN UNIVERSITY OF RAS AL KHAIMAH   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 2; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BIK GENE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENE REPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS LATENCY; WILD TYPE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; CELL LINE; DOWN-REGULATION; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; MEMBRANE PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; VIRAL PROTEINS;

EID: 84897539829     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03642-13     Document Type: Article

References (109)

1. Pattle SB, Farrell PJ. 2006.Therole of Epstein-Barr virus in cancer. Expert Opin. Biol. Ther. 6:1193-1205. http://dx.doi.org/10.1517/14712598.6.11.1193.
2. Kieff E, Rickinson AB. 2007. Epstein-Barr virus, p 2603-2654. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott-Williams & Wilkins, Philadelphia, PA.
3. Young LS, Arrand JR, Murray PG. 2007. EBV gene expression and regulation, p 461-489. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
4. Lopes LF, Ruiz Miyazawa KW, de Almeida ER, Serafim KG, de Almeida Gualtieri K, Costa IC, Felipe I, Pavanelli WR, Watanabe MA. 2013. Epstein-Barr virus (EBV) microRNAs: involvement in cancer pathogenesis and immunopathology. Int. Rev. Immunol. 32:271-281. http://dx.doi.org/10.3109/08830185.2012.748053.
5. Zimber-Strobl U, Strobl LJ. 2001. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin. Cancer Biol. 11:423-434. http://dx.doi.org/10.1006/scbi.2001.0409.
6. Hayward SD. 2004. Viral interactions with the Notch pathway. Semin. Cancer Biol. 14:387-396. http://dx.doi.org/10.1016/j.semcancer.2004.04.018.
7. Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E. 1990. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64:3407-3416.
8. Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B. 1999. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73:4481-4484.
9. Soni V, Cahir-McFarland E, Kieff E. 2007. LMP1 TRAFficking activates growth and survival pathways. Adv. Exp. Med. Biol. 597:173-187. http://dx.doi.org/10.1007/978-0-387-70630-6_14.
10. Fernandez D, Sanchez-Arevalo VJ, de Alboran IM. 2012. The role of the proto-oncogene c-myc in B lymphocyte differentiation. Crit. Rev. Immunol. 32:321-334. http://dx.doi.org/10.1615/CritRevImmunol.v32.i4.30.
11. Allen CD, Okada T, Cyster JG. 2007. Germinal-center organization and cellular dynamics. Immunity 27:190-202. http://dx.doi.org/10.1016/j.immuni.2007.07.009.
12. Hummel M, Anagnostopoulos I, Korbjuhn P, Stein H. 1995. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low-and high-grade types. J. Pathol. 175:263-271.
13. Kurth J, Spieker T, Wustrow J, Strickler GJ, Hansmann LM, Rajewsky K, Kuppers R. 2000. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13:485-495. http://dx.doi.org/10.1016/S1074-7613 (00)00048-0.
14. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. 1995. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 85:744-750.
15. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. 2013. The pathogenesis of Epstein-Barr virus persistent infection. Curr. Opin. Virol. 3:227-232. http://dx.doi.org/10.1016/j.coviro.2013.04.005.
16. Rowe M, Kelly GL, Bell AI, Rickinson AB. 2009. Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin. Cancer Biol. 19:377-388. http://dx.doi.org/10.1016/j.semcancer.2009.07.004.
17. Kuppers R. 2002. Molecular biology of Hodgkin's lymphoma. Adv. Cancer Res. 84:277-312. http://dx.doi.org/10.1016/s0065-230x(02)84009-x.
18. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080-1085.
19. Spender LC, Inman GJ. 2011. Inhibition of germinal centre apoptotic programs by Epstein-Barr virus. Adv. Hematol. 2011:829525. http://dx.doi.org/10.1155/2011/829525.
20. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-768. http://dx.doi.org/10.1038/nrc1452.
21. Kutok JL, Wang F. 2006. Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol. 1:375-404. http://dx.doi.org/10.1146/annurev.pathol.1.110304.100209.
22. Spender LC, O'Brien DI, Simpson D, Dutt D, Gregory CD, Allday MJ, Clark LJ, Inman GJ. 2009. TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL. Cell Death Differ. 16: 593-602. http://dx.doi.org/10.1038/cdd.2008.183.
23. Inman GJ, Allday MJ. 2000. Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent. J. Immunol. 165:2500-2510.
24. Klein U, Dalla-Favera R. 2008. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8:22-33. http://dx.doi.org/10.1038/nri2217.
25. Hao Z, Duncan GS, Seagal J, Su YW, Hong C, Haight J, Chen NJ, Elia A, Wakeham A, Li WY, Liepa J, Wood GA, Casola S, Rajewsky K, Mak TW. 2008. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity 29:615-627. http://dx.doi.org/10.1016/j.immuni.2008.07.016.
26. Romero-Camarero I, Jiang X, Natkunam Y, Lu X, Vicente-Duenas C, Gonzalez-Herrero I, Flores T, Garcia JL, McNamara G, Kunder C, Zhao S, Segura V, Fontan L, Martinez-Climent JA, Garcia-Criado FJ, Theis JD, Dogan A, Campos-Sanchez E, Green MR, Alizadeh AA, Cobaleda C, Sanchez-Garcia I, Lossos IS. 2013. Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCRmediated Syk activation. Nat. Commun. 4:1338. http://dx.doi.org/10.1038/ncomms2334.
27. Cory S, Huang DC, Adams JM. 2003. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590-8607. http://dx.doi.org/10.1038/sj.onc.1207102.
28. Willis SN, Adams JM. 2005. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17:617-625. http://dx.doi.org/1 0.1016/j.ceb.2005.10.001.
29. Cory S, Adams JM. 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2:647-656. http://dx.doi.org/10.1038/nrc883.
30. Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL. 2006. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett. 580:5905-5909. http://dx.doi.org/10.1016/j.febslet.2006.08.088.
31. Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T. 2006. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res. 66:10153-10161. http://dx.doi.org/10.1158/0008-5472.CAN-05-3696.
32. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, Wajant H. 2001. p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20:571-580. http://dx.doi.org/10.1038/sj.onc.1204124.
33. Mathai JP, Germain M, Marcellus RC, Shore GC. 2002. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene 21:2534-2544. http://dx.doi.org/10.1038/sj/onc/1205340.
34. Chinnadurai G, Vijayalingam S, Rashmi R. 2008. BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Oncogene 27(Suppl. 1):S20-S29. http://dx.doi.org/10.1038/onc.2009.40.
35. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. 2005. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17:393-403. http://dx.doi.org/10.1016/j.molcel.2004.12.030.
36. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dorken B, Brown R. 1999. Expression of the death gene Bik/Nbk promotes sensitivity to druginduced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood 94:1100-1107.
37. Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, Hung MC. 2002. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res. 62:8-12.
38. Sturm I, Stephan C, Gillissen B, Siebert R, Janz M, Radetzki S, Jung K, Loening S, Dorken B, Daniel PT. 2006. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ. 13:619-627. http://dx.doi.org/10.1038/sj.cdd.4401782.
39. Tong Y, Yang Q, Vater C, Venkatesh LK, Custeau D, Chittenden T, Chinnadurai G, Gourdeau H. 2001. The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain. Mol. Cancer Ther. 1:95-102.
40. Coultas L, Bouillet P, Stanley EG, Brodnicki TC, Adams JM, Strasser A. 2004. Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programd death. Mol. Cell. Biol. 24:1570-1581. http://dx.doi.org/10.1128/MCB.24.4.1570-1581.2004.
41. Jiang A, Clark EA. 2001. Involvement of Bik, a proapoptotic member of the Bcl-2 family, in surface IgM-mediated B cell apoptosis. J. Immunol. 166:6025-6033.
42. Kelly G, Bell A, Rickinson A. 2002. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8:1098-1104. http://dx.doi.org/10.1038/nm758.
43. Andersson ML, Stam NJ, Klein G, Ploegh HL, Masucci MG. 1991. Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells. Int. J. Cancer 47:544-550.
44. Ben-Bassat H, Goldblum N, Mitrani S, Goldblum T, Yoffey JM, Cohen MM, Bentwich Z, Ramot B, Klein E, Klein G. 1977. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int. J. Cancer 19:27-33.
45. Gregory CD, Rowe M, Rickinson AB. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
46. Klein G, Giovanella B, Westman A, Stehlin JS, Mumford D. 1975. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5:319-334.
47. Menezes J, Leibold W, Klein G, Clements G. 1975. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22:276-284.
48. Rowe M, Rooney CM, Edwards CF, Lenoir GM, Rickinson AB. 1986. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int. J. Cancer 37:367-373.
49. Kelly GL, Milner AE, Tierney RJ, Croom-Carter DS, Altmann M, Hammerschmidt W, Bell AI, Rickinson AB. 2005. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A,-3B, and-3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79:10709-10717. http://dx.doi.org/10.1128/JVI.79.16.10709-10717.2005.
50. Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, Delecluse HJ, Rottenberger C, Bornkamm GW, Hammerschmidt W. 1995. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2.EMBOJ. 14:88-96.
51. Kempkes B, Zimber-Strobl U, Eissner G, Pawlita M, Falk M, Hammerschmidt W, Bornkamm GW. 1996. Epstein-Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein-Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines. J. Gen. Virol. 77:227-237.
52. Floettmann JE, Ward K, Rickinson AB, Rowe M. 1996. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology 223:29-40.
53. Kempkes B, Pawlita M, Zimber-Strobl U, Eissner G, Laux G, Bornkamm GW. 1995. Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Virology 214:675-679.
54. Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, Eick D, Kohlhuber F. 1999. Control of cell growth by c-Myc in the absence of cell division. Curr. Biol. 9:1255-1258.
55. Maier S, Santak M, Mantik A, Grabusic K, Kremmer E, Hammerschmidt W, Kempkes B. 2005. A somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulinM is partially CBF1 independent. J. Virol. 79:8784-8792. http://dx.doi.org/10.1128/JVI.79.14.8784-8797.2005.
56. Gordadze AV, Peng R, Tan J, Liu G, Sutton R, Kempkes B, Bornkamm GW, Ling PD. 2001. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J. Virol. 75:5899-5912. http://dx.doi.org/10.1128/JVI.75.13.5899-5912.2001.
57. Altmann M, Hammerschmidt W. 2005. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. 3(12):e404. http://dx.doi.org/10.1371/journal.pbio.0030404.
58. Shannon-Lowe C, Adland E, Bell AI, Delecluse HJ, Rickinson AB, Rowe M. 2009. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J. Virol. 83:7749-7760. http://dx.doi.org/10.1128/JVI.00108-09.
59. Shannon-Lowe C, Baldwin G, Feederle R, Bell A, Rickinson A, Delecluse HJ. 2005. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J. Gen. Virol. 86: 3009-3019. http://dx.doi.org/10.1099/vir.0.81153-0.
60. Heath E, Begue-Pastor N, Chaganti S, Croom-Carter D, Shannon-Lowe C, Kube D, Feederle R, Delecluse HJ, Rickinson AB, Bell AI. 2012. Epstein-Barr virus infection of naive B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology. PLoS Pathog. 8(5):e1002697. http://dx.doi.org/10.1371/journal.ppat.1002697.
61. Loughran ST, Campion EM, D'Souza BN, Smith SM, Vrzalikova K, Wen K, Murray PG, Walls D. 2011. Bfl-1 is a crucial pro-survival nuclear factor-κB target gene in Hodgkin/Reed-Sternberg cells. Int. J. Cancer 129:2787-2796. http://dx.doi.org/10.1002/ijc.25950.
62. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔCT) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
63. D'Souza BN, Edelstein LC, Pegman PM, Smith SM, Loughran ST, Clarke A, Mehl A, Rowe M, Gelinas C, Walls D. 2004. Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J. Virol. 78:1800-1816. http://dx.doi.org/10.1128/JVI.78.4.1800-1816.2004.
64. Finke J, Rowe M, Kallin B, Ernberg I, Rosen A, Dillner J, Klein G. 1987. Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J. Virol. 61:3870-3878.
65. Ling PD, Rawlins DR, Hayward SD. 1993. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc. Natl. Acad. Sci. U. S. A. 90:9237-9241.
66. Gordadze AV, Poston D, Ling PD. 2002. The EBNA2 polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance. J. Virol. 76:7349-7355. http://dx.doi.org/10.1128/JVI.76.14.7349-7355.2002.
67. Hur J, Chesnes J, Coser KR, Lee RS, Geck P, Isselbacher KJ, Shioda T. 2004. The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc. Natl. Acad. Sci. U. S. A. 101:2351-2356. http://dx.doi.org/10.1073/pnas.0307337101.
68. Polack A, Hortnagel K, Pajic A, Christoph B, Baier B, Falk M, Mautner J, Geltinger C, Bornkamm GW, Kempkes B. 1996. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl. Acad. Sci. U. S. A. 93:10411-10416.
69. Tierney RJ, Kao KY, Nagra JK, Rickinson AB. 2011. Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J. Virol. 85: 12362-12375. http://dx.doi.org/10.1128/JVI.06059-11.
70. Klein G, Lindahl T, Jondal M, Leibold W, Menezes J, Nilsson K, Sundstrom C. 1974. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc. Natl. Acad. Sci. U. S. A. 71:3283-3286.
71. Schuster N, Krieglstein K. 2002. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res. 307:1-14. http://dx.doi.org/10.1007/s00441-001-0479-6.
72. Magae J, Illenye S, Tejima T, Chang YC, Mitsui Y, Tanaka K, Omura S, Heintz NH. 1997. Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin. Oncogene 15:759-769.
73. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B. 2005. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib( PS-341,Velcade)andotherproteasomeinhibitors.Oncogene24:4993-4999. http://dx.doi.org/10.1038/sj.onc.1208683.
74. Germain M, Mathai JP, Shore GC. 2002. BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria. J. Biol. Chem. 277:18053-18060. http://dx.doi.org/10.1074/jbc.M201235200.
75. 2+ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death. J. Biol. Chem. 280:23829-23836. http://dx.doi.org/10.1074/jbc.M500800200.
76. Zhao X, Sun Y, Yu H, Ye L, Zhang L, Lu J, Yuan Y, Qian G, Ge S. 2007. Apoptosis induced by BIK was decreased with RNA interference of caspase-12. Biochem. Biophys. Res. Commun. 359:896-901. http://dx.doi.org/10.1016/j.bbrc.2007.05.175.
77. Kehrl JH, Taylor AS, Delsing GA, Roberts AB, Sporn MB, Fauci AS. 1989. Further studies of the role of transforming growth factor-beta in human B cell function. J. Immunol. 143:1868-1874.
78. Kumar A, Rogers T, Maizel A, Sharma S. 1991. Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBVtransformed human B cells. J. Immunol. 147:998-1006.
79. Inman GJ, Allday MJ. 2000. Resistance to TGF-β1 correlates with a reduction of TGF-β type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J. Gen. Virol. 81:1567-1578.
80. Altiok A, Ehlin-Henriksson B, Klein E. 1993. Correlation between the growth-inhibitory effect of TGF-beta 1 and phenotypic characteristics in a panel of B-cell lines. Int. J. Cancer 55:137-140.
81. Schrantz N, Blanchard DA, Auffredou MT, Sharma S, Leca G, Vazquez A. 1999. Role of caspases and possible involvement of retinoblastoma protein during TGF-beta-mediated apoptosis of human B lymphocytes. Oncogene 18:3511-3519.
82. Shimazu T, Degenhardt K, Nur-E-Kamal A, Zhang J, Yoshida T, Zhang Y, Mathew R, White E, Inouye M. 2007. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev. 21:929-941. http://dx.doi.org/10.1101/gad.1522007.
83. Kvansakul M, Wei AH, Fletcher JI, Willis SN, Chen L, Roberts AW, Huang DC, Colman PM. 2010. Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. PLoS Pathog. 6(12):e1001236. http://dx.doi.org/10.1371/journal.ppat.1001236.
84. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ. 1995. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11:1921-1928.
85. Elangovan B, Chinnadurai G. 1997. Functional dissection of the proapoptotic protein Bik. Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death. J. Biol. Chem. 272:24494-24498.
86. D'Souza B, Rowe M, Walls D. 2000. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line. J. Virol. 74:6652-6658. http://dx.doi.org/10.1128/JVI.74.14.6652-6658.2000.
87. Gillissen B, Essmann F, Hemmati PG, Richter A, Richter A, Oztop I, Chinnadurai G, Dorken B, Daniel PT. 2007. Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J. Cell Biol. 179:701-715. http://dx.doi.org/10.1083/jcb.200703040.
88. Arena V, Martini M, Luongo M, Capelli A, Larocca LM. 2003. Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer 38:91-96. http://dx.doi.org/10.1002/gcc.10245.
89. Schrantz N, Bourgeade MF, Mouhamad S, Leca G, Sharma S, Vazquez A. 2001. p38-mediated regulation of an Fas-associated death domain protein-independent pathway leading to caspase-8 activation during TGF-beta-induced apoptosis in human Burkitt lymphoma B cells BL41. Mol. Biol. Cell 12:3139-3151. http://dx.doi.org/10.1091/mbc.12.10.3139.
90. Altiok A, Bejarano MT, Ruscetti F, Altiok E, Klein G, Klein E. 1991. Effect of transforming growth factor-beta 1 and-beta 2 on the proliferation of Burkitt lymphoma and lymphoblastoid cell lines. Growth Factors 4:117-128.
91. Fukuda M, Kurosaki H, Sairenji T. 2006. Loss of functional transforming growth factor (TGF)-β type II receptor results in insensitivity to TGF-β1-mediated apoptosis and Epstein-Barr virus reactivation. J. Med. Virol. 78:1456-1464. http://dx.doi.org/10.1002/jmv.20719.
92. Horndasch M, Raschke EE, Bommer G, Schuhmacher M, Dumont E, Kuklik-Roos C, Eick D, Kempkes B. 2002. Epstein-Barr virus antagonizes the antiproliferative activity of transforming growth factor-beta but does not abolish its signaling. Int. J. Cancer 101:442-447. http://dx.doi.org/10.1002/ijc.10626.
93. Rochford R, Cannon MJ, Sabbe RE, Adusumilli K, Picchio G, Glynn JM, Noonan DJ, Mosier DE, Hobbs MV. 1997. Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines. Viral Immunol. 10:183-195.
94. Wroblewski JM, Copple A, Batson LP, Landers CD, Yannelli JR. 2002. Cell surface phenotyping and cytokine production of Epstein-Barr virus (EBV)-transformedlymphoblastoidcell lines(LCLs).J.Immunol.Methods264:19-28. http://dx.doi.org/10.1016/S0022-1759(01)00565-8.
95. Lee JM, Lee KH, Farrell CJ, Ling PD, Kempkes B, Park JH, Hayward SD. 2004. EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J. Virol. 78: 12694-12697. http://dx.doi.org/10.1128/JVI.78.22.12694-12697.2004.
96. Lee JM, Lee KH, Weidner M, Osborne BA, Hayward SD. 2002. Epstein-Barr virus EBNA2 blocks Nur77-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 99:11878-11883. http://dx.doi.org/10.1073/pnas.182552499.
97. Pegman PM, Smith SM, D'Souza BN, Loughran ST, Maier S, Kempkes B, Cahill PA, Simmons MJ, Gelinas C, Walls D. 2006. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. J. Virol. 80:8133-8144. http://dx.doi.org/10.1128/JVI.00278-06.
98. Kenney JL, Guinness ME, Reiss M, Lacy J. 2001. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents. Int. J. Cancer 91:89-98. http://dx.doi.org/10.1002/1097-0215(20010101)91:1<89::AID-IJC1015>3.0.CO;2-U.
99. Lo AK, Dawson CW, Lo KW, Yu Y, Young LS. 2010. Upregulation of Id1 by Epstein-Barr virus-encoded LMP1 confers resistance to TGFbeta-mediated growth inhibition. Mol. Cancer 9:155. http://dx.doi.org/10.1186/1476-4598-9-155.
100. Miller WE, Earp HS, Raab-Traub N. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 69:4390-4398.
101. Klein U, Tu Y, Stolovitzky GA, Keller JL, Haddad Jr, Miljkovic JV, Cattoretti G, Califano A, Dalla-Favera R. 2003. Gene expression dynamics during germinal center transit in B cells. Ann. N. Y. Acad. Sci. 987:166-172. http://dx.doi.org/10.1111/j.1749-6632.2003.tb06045.x.
102. Joseph AM, Babcock GJ, Thorley-Lawson DA. 2000. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J. Virol. 74:9964-9971. http://dx.doi.org/10.1128/JVI.74.21.9964-9971.2000.
103. Spender LC, Cornish GH, Sullivan A, Farrell PJ. 2002. Expression of transcription factor AML-2 (RUNX3, CBFβ-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J. Virol. 76:4919-4927. http://dx.doi.org/10.1128/JVI.76.10.4919-4927.2002.
104. Verma S, Budarf ML, Emanuel BS, Chinnadurai G. 2000. Structural analysis of the human pro-apoptotic gene Bik: chromosomal localization, genomic organization and localization of promoter sequences. Gene 254:157-162. http://dx.doi.org/10.1016/S0378-1119(00)00276-6.
105. Milutinovic S, Brown SE, Zhuang Q, Szyf M. 2004. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J. Biol. Chem. 279: 27915-27927. http://dx.doi.org/10.1074/jbc.M312823200.
106. Amanna IJ, Dingwall JP, Hayes CE. 2003. Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J. Immunol. 170:4593-4600.
107. Hegde R, Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. 1998. Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J. Biol. Chem. 273:7783-7786.
108. Subramanian T, Vijayalingam S, Lomonosova E, Zhao LJ, Chinnadurai G. 2007. Evidence for involvement of BH3-only proapoptotic members in adenovirus-induced apoptosis. J. Virol. 81:10486-10495. http://dx.doi.org/10.1128/JVI.00808-07.
109. Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, Ganem D, Middeldorp J, Wiertz EJ, Ressing ME. 2007. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc. Natl. Acad. Sci. U. S. A. 104:3366-3371. http://dx.doi.org/10.1073/pnas.0611128104.